Clinical Trial Update: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels [Phase 2]

View source ↗

Summary

Phase 2 Yale-sponsored trial evaluating adding sequential cytoreductive intervention to standard-of-care therapy for metastatic foregut adenocarcinomas with und…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ampullary Adenocarcinoma
• Duodenal Adenocarcinoma
• Esophageal Adenocarcinoma
• Foregut Adenocarcinoma
• Gallbladder Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Adenocarcinoma
• Pancreas Adenocarcinoma

Snippet

Sponsor: Yale University | Conditions: Foregut Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Status: RECRUITING